179 related articles for article (PubMed ID: 35008254)
1. Editorial on Special Issue "Immunotherapy, Tumor Microenvironment and Survival Signaling".
Golubovskaya V
Cancers (Basel); 2021 Dec; 14(1):. PubMed ID: 35008254
[TBL] [Abstract][Full Text] [Related]
2. Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.
Chung C
Pharmacotherapy; 2017 Jan; 37(1):129-143. PubMed ID: 27870103
[TBL] [Abstract][Full Text] [Related]
3. Any closer to successful therapy of multiple myeloma? CAR-T cell is a good reason for optimism.
Marofi F; Tahmasebi S; Rahman HS; Kaigorodov D; Markov A; Yumashev AV; Shomali N; Chartrand MS; Pathak Y; Mohammed RN; Jarahian M; Motavalli R; Motavalli Khiavi F
Stem Cell Res Ther; 2021 Mar; 12(1):217. PubMed ID: 33781320
[TBL] [Abstract][Full Text] [Related]
4. Befriending the Hostile Tumor Microenvironment in CAR T-Cell Therapy.
Lindo L; Wilkinson LH; Hay KA
Front Immunol; 2020; 11():618387. PubMed ID: 33643299
[TBL] [Abstract][Full Text] [Related]
5. Targeting the Immune Niche within the Bone Marrow Microenvironment: The Rise of Immunotherapy in Multiple Myeloma.
Podar K; Jager D
Curr Cancer Drug Targets; 2017; 17(9):782-805. PubMed ID: 28201977
[TBL] [Abstract][Full Text] [Related]
6. CAR T Cells with Enhanced Sensitivity to B Cell Maturation Antigen for the Targeting of B Cell Non-Hodgkin's Lymphoma and Multiple Myeloma.
Bluhm J; Kieback E; Marino SF; Oden F; Westermann J; Chmielewski M; Abken H; Uckert W; Höpken UE; Rehm A
Mol Ther; 2018 Aug; 26(8):1906-1920. PubMed ID: 30078440
[TBL] [Abstract][Full Text] [Related]
7. [Chimeric antigen receptor T-cell therapy for multiple myeloma].
Hosen N
Rinsho Ketsueki; 2018; 59(10):2189-2194. PubMed ID: 30305525
[TBL] [Abstract][Full Text] [Related]
8. Hematopoietic versus Solid Cancers and T Cell Dysfunction: Looking for Similarities and Distinctions.
Montironi C; Muñoz-Pinedo C; Eldering E
Cancers (Basel); 2021 Jan; 13(2):. PubMed ID: 33466674
[TBL] [Abstract][Full Text] [Related]
9. Next Generation CAR T Cells for the Immunotherapy of High-Grade Glioma.
Petersen CT; Krenciute G
Front Oncol; 2019; 9():69. PubMed ID: 30863720
[TBL] [Abstract][Full Text] [Related]
10. Novel progresses of chimeric antigen receptor (CAR) T cell therapy in multiple myeloma.
Ding L; Hu Y; Huang H
Stem Cell Investig; 2021; 8():1. PubMed ID: 33575314
[TBL] [Abstract][Full Text] [Related]
11. Chimeric antigen receptor T-cell lymphoma immunotherapy: the next questions.
Salaroli A; Spilleboudt C; Bron D; Lewalle P
Curr Opin Oncol; 2020 Sep; 32(5):434-441. PubMed ID: 32796231
[TBL] [Abstract][Full Text] [Related]
12. Cellular Immunotherapy in the Treatment of Hematopoietic Malignancies.
Matsueda S; Chodon T; Koya RC
Adv Exp Med Biol; 2019; 1143():217-229. PubMed ID: 31338822
[TBL] [Abstract][Full Text] [Related]
13. Chimeric antigen receptor T cell therapy for multiple myeloma.
Hasegawa K; Hosen N
Inflamm Regen; 2019; 39():10. PubMed ID: 31171941
[TBL] [Abstract][Full Text] [Related]
14. Clinical Efficacy and Tumor Microenvironment Influence in a Dose-Escalation Study of Anti-CD19 Chimeric Antigen Receptor T Cells in Refractory B-Cell Non-Hodgkin's Lymphoma.
Yan ZX; Li L; Wang W; OuYang BS; Cheng S; Wang L; Wu W; Xu PP; Muftuoglu M; Hao M; Yang S; Zhang MC; Zheng Z; Li J; Zhao WL
Clin Cancer Res; 2019 Dec; 25(23):6995-7003. PubMed ID: 31444250
[TBL] [Abstract][Full Text] [Related]
15. Emerging Approaches for Solid Tumor Treatment Using CAR-T Cell Therapy.
Chung H; Jung H; Noh JY
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830003
[TBL] [Abstract][Full Text] [Related]
16. Cellular Immunotherapy in B-Cell Malignancy.
Schwarzbich MA; Witzens-Harig M
Oncol Res Treat; 2017; 40(11):674-681. PubMed ID: 29065420
[TBL] [Abstract][Full Text] [Related]
17. Understanding the Immune-Stroma Microenvironment in B Cell Malignancies for Effective Immunotherapy.
Apollonio B; Ioannou N; Papazoglou D; Ramsay AG
Front Oncol; 2021; 11():626818. PubMed ID: 33842331
[TBL] [Abstract][Full Text] [Related]
18. Effective Targeting of Multiple B-Cell Maturation Antigen-Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells.
Friedman KM; Garrett TE; Evans JW; Horton HM; Latimer HJ; Seidel SL; Horvath CJ; Morgan RA
Hum Gene Ther; 2018 May; 29(5):585-601. PubMed ID: 29641319
[TBL] [Abstract][Full Text] [Related]
19. Current advances in chimeric antigen receptor T-cell therapy for refractory/relapsed multiple myeloma.
Huang H; Wu HW; Hu YX
J Zhejiang Univ Sci B; 2020 Jan.; 21(1):29-41. PubMed ID: 31898440
[TBL] [Abstract][Full Text] [Related]
20. Heat Shock Proteins in Lymphoma Immunotherapy.
Albakova Z; Mangasarova Y; Sapozhnikov A
Front Immunol; 2021; 12():660085. PubMed ID: 33815422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
